Walters Group buys 4.34M Zentalis shares at $3.50

Zentalis Pharmaceuticals, Inc. (ZNTL) reported that The Walters Group, a ten percent owner, purchased 4,335,000 shares of common stock in an open-market or private transaction at $3.50 per share on August 14, 2026.

Rhea-AI Filing Summary

Zentalis Pharmaceuticals, Inc. (ZNTL) reported that The Walters Group, a ten percent owner, purchased 4,335,000 shares of common stock in an open-market or private transaction at $3.50 per share on August 14, 2026. Following this purchase, The Walters Group directly holds 17,844,973 shares. William T. Walters and Susan B. Walters may be deemed to share voting and dispositive power over these shares but each reporting person disclaims Section 16 beneficial ownership except to the extent of any pecuniary interest.

Insider Trade Summary

Net Buyer: 4,335,000 shares

Net Buy 1 txn

Insider WALTERS GROUP, WALTERS WILLIAM THURMAN, WALTERS SUSAN BERKLEY

Role 10% Owner | 10% Owner | 10% Owner

Bought 4,335,000 shs ($15.17M)

Type	Security	Shares	Price	Value
Purchase	Common Stock F1	4,335,000	$3.50	$15.17M

Holdings After Transaction: Common Stock — 17,844,973 shares (Direct)

Footnotes (1)

1. F1. The shares of common stock reported herein (the "Shares") are held directly by The Walters Group (the "TWG"). William T. Walters may be deemed to share voting and dispositive power with respect to the Shares. Susan B. Walters is the general partner and majority member of TWG and may be deemed to share voting and dispositive power with respect to the Shares. Each Reporting Person disclaims Section 16 beneficial ownership of the Shares reported herein except to the extent of its pecuniary interest therein, if any, and the inclusion of these Shares in this report shall not be deemed an admission of beneficial ownership of any of the reported Shares for purposes of Section 16 or any other purpose.

Key Figures

Shares purchased: 4,335,000 shares Purchase price: $3.50 per share Post-transaction holdings: 17,844,973 shares +1 more

4 metrics

Shares purchased 4,335,000 shares Common stock acquired on August 14, 2026

Purchase price $3.50 per share Price paid by The Walters Group for ZNTL common stock

Post-transaction holdings 17,844,973 shares ZNTL common stock held directly by The Walters Group after the transaction

Net buy shares 4,335,000 shares Net share change across all reported transactions in this Form 4

Key Terms

Section 16 beneficial ownership, voting and dispositive power, pecuniary interest

3 terms

Section 16 beneficial ownership regulatory

"Each Reporting Person disclaims Section 16 beneficial ownership of the Shares"

voting and dispositive power regulatory

"may be deemed to share voting and dispositive power with respect to the Shares"

pecuniary interest financial

"except to the extent of its pecuniary interest therein, if any"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction was reported for ZNTL in this Form 4?

The filing reports that The Walters Group purchased 4,335,000 shares of Zentalis Pharmaceuticals common stock at $3.50 per share on August 14, 2026, in an open-market or private transaction.

How many ZNTL shares does The Walters Group own after this transaction?

After the reported purchase, The Walters Group holds 17,844,973 shares of Zentalis Pharmaceuticals common stock. This figure reflects its direct ownership position as reported in the Form 4 following the August 14, 2026 transaction.

Who are the reporting persons in this ZNTL Form 4 filing?

The reporting persons are The Walters Group, William T. Walters, and Susan B. Walters, each identified as a ten percent owner of Zentalis Pharmaceuticals for Section 16 reporting purposes in this Form 4.

Do William and Susan Walters directly own the reported ZNTL shares?

The shares are held directly by The Walters Group. William T. Walters and Susan B. Walters may be deemed to share voting and dispositive power, but each disclaims beneficial ownership except to any pecuniary interest.

Was the ZNTL insider trade made under a Rule 10b5-1 trading plan?

The Form 4 indicates that the Rule 10b5-1 checkbox is not marked, meaning the transaction is not affirmed as made pursuant to a Rule 10b5-1 trading plan in this filing.

What was the price paid per share in the ZNTL insider purchase?

The Walters Group paid $3.50 per share for the 4,335,000 shares of Zentalis Pharmaceuticals common stock acquired on August 14, 2026, as reported in the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/19/2026 - 06:11 PM Accepted by SEC EDGAR 08/19/2026 - 06:11 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WALTERS GROUP

(Last) (First) (Middle)

8975 S. PECOS ROAD

UNIT 6A

(Street)

HENDERSON NEVADA 89074

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Zentalis Pharmaceuticals, Inc. [ ZNTL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/14/2026		P		4,335,000(1)	A	$3.5	17,844,973(1)	D(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

WALTERS GROUP

(Last) (First) (Middle)

8975 S. PECOS ROAD

UNIT 6A

(Street)

HENDERSON NEVADA 89074

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

WALTERS WILLIAM THURMAN

(Last) (First) (Middle)

8975 S. PECOS ROAD

UNIT 6A

(Street)

HENDERSON NEVADA 89074

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

WALTERS SUSAN BERKLEY

(Last) (First) (Middle)

8975 S. PECOS ROAD

UNIT 6A

(Street)

HENDERSON NEVADA 89074

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. The shares of common stock reported herein (the "Shares") are held directly by The Walters Group (the "TWG"). William T. Walters may be deemed to share voting and dispositive power with respect to the Shares. Susan B. Walters is the general partner and majority member of TWG and may be deemed to share voting and dispositive power with respect to the Shares. Each Reporting Person disclaims Section 16 beneficial ownership of the Shares reported herein except to the extent of its pecuniary interest therein, if any, and the inclusion of these Shares in this report shall not be deemed an admission of beneficial ownership of any of the reported Shares for purposes of Section 16 or any other purpose.

	The Walters Group, By: Susan B. Walters, Name: Susan B. Walters, Title: General Partner	08/19/2026
	William T. Walters	08/19/2026
	Susan B. Walters	08/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)